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Abstract: Previous clinical evaluation of FK506 in renal transplantation 
has demonstrated equivalent patient and graft survival when compared 
with cyclosporine-based regimens. However. lower steroid and anti-hyper-
tensive medication requirements and lower serum cholesterol levels have been 
seen in patients receiving FK506. In August, 1991, a prospective, ran-
domized trial was begun. comparing FK506/ prednisone with FK506/ aza-
thioprine/ prednisone. Two-hundred-and-four adults were entered into this 
trial between August I, 1991. and October II, 1992. The mean recipient 
age was 43.8 ± 13.7 years, with a range of 17.6-78.0 years. Sixty-one (30"10) 
recipients received a 2nd, 3rd or 4th transplant, while 35 (17%) had a PRA 
greater than 40% at the time of transplant. Thirty-three (16%) of the trans-
plants were in recipients over 60 years of age, Thirteen percent of the kidneys 
were from living donors; 13% of the cadaveric kidneys were from pediatric 
donors less than 3 years of age and were transplanted en bloc. The mean cold 
ischemia time was 31.4 ± 8.4 hours. and the mean donor age was 34 ± 2.1 0 
years, with a range from 4 months to 75 years. With a mean follow-up of9 ± 4 
months, the I-year actuarial patient survival is 93%; for the two-drug group 
it is 95%, and for the three-drug group it is 91 % (p = NS). One-year actu-
arial graft survival is 86%; in the two-drug group it is 90%, while in the 
three-drug group it is 82% (p = NS). The mean serum creatir.ine and BUN 
are 1.85 ± 0.76 mg/ dl and 30 ± 14 mg/ dl; the values are not significantly 
different between the two- and lhree-drug groups. Rejection was seen in 45% 
of patients, 51 % in the two-drug and 39% in the three-drug group (p = 0.09). 
In cadaveric recipients, more rejection was seen in the two-drug group 
(58%) than in the three-drug group (39%; p < 0.02: 24 (I :Z01o) of patients 
required OKT3 or ATGAM® for rejection: 24 (12%) had cytomegalovirus; 
an equal incidence was seen in both groups. New onset diabetes was seen in 
14% of patients; there was a higher incidence in the two-drug (20"10) than 
in the three-drug (8%) group (p < 0.03). The incidence of PTLD was 1%(2 
patients). Crossover between the two limbs was seen commonly: 26/25%) 
of the patients in the two-drug group required the addition of azathioprine, 
while 46 (45%) of the patients in the three-drug group required discontinu-
ation of azathioprine (usually because of a falling white blood cell count or 
hepatic dysfunction). Sixty-five (32%) patients are off steroids, while 88 (43%) 
patients are not taking any antihypertensive medications. The mean serum 
cholesterol is 193 ± 53 mgt dl. These data confum earlier repons about the 
efficacy of FK506 in renal transplantation. The benefit of azathioprine is 
unclear, with no improvement in patient and graft survival and a higher 
crossover rate, but with less rejection in certain subgroups and less diabetes. 
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Introduction 
The new immunosuppressive drug FK-506 has 
been used as the primary agent after transplan-
tation of nearly all organs, including the liver (1), 
kidney (2), heart (3), lung (4), small intestine (6) 
and pancreatic islets (7). The early experiences in 
renal transplantation have been encouraging (2, 
7-12). A large comparative experience between 
cyc1osporine and FK-506 revealed equivalent pa-
tient and graft survival, but improved results with 
FK-506 in terms of secondary outcomes - lower 
steroids and antihypertensive requirements, and 
lower serum cholesterol levels (8). On the basis of 
these earlier studies. a prospective, randomized tri-
al was begun to evaluate two different FK-506-
based regimens, with and withoug azathioprine. 
A preliminary report of this trial, while showing 
promising results, was limited by the short follow-
up (9); l-yr actuarial data are now available for 
presentation. 
Mlterlll 1111 lad Ids 
Entry criteria 
Between 1 August, 1991, and 11 October, 1992, 
204 patients were entered into a randomized trial 
comparing FK-506 and prednisone with FK-506, 
azathioprine, and prednisone. Adult patients 
ur.dergoing kidney transplantation only who 
agreed to participate in the trial were eligible. Pedi-
atric patients, patients receiving another organ 
concomitanly (liver or pancreatic islets), or patients 
who refused were not entered into the trial. The 
protocol was reviewed and approved by the Insti-
tutional Review Board of the University of Pitts-
burgh. . 
Recipient characteristics 
The mean recipient age was 43.8 ± 13.7 yr, with a 
range of 17.6-78 yr (Table I). Sixty-one (30%) pa-
Table 1. Recipient characteristics 
FK506/pred FK506laza1pred Overall 
Patients 102 102 204 
Mean recipient age 42.1 :1:13.1 yr 45.4:1:14.1 yr 43.8:1:13.7 yr 
(Range) (17.6-09.6) (18.1-78.0) (17.6-78.0) 
1 51 transplant 73 (72'W.) 70 (69%) 143 (70'lr.) 
Retrclnsplant 29 (m) 32 (31%) 61 (3O'lr.) 
PM ~4M% 17 (In.) 20 (2O'lr.) 37 (18%) 
• Age ~ 60 years 11 (11%) 22 (22%) 33 (16') 
Non-bIack 89 EU~F 87 (85') 176 (86%) 
Black 13 E1~F 15 (15%) 28 (14\\ 
• p<O.04. 
FK-506: double- vs. triple-drug therapy 
tients were undergoing retransplantation, receiving 
their 2nd (41-20%), 3rd (15-7%), or 4th (5-3%) 
transplant. Thirty-seven (18%) patients had a 
panel-reactive antibody (PRA) greater than 40% 
at the time of transplantation. Thirty-three (16%) 
of the recipients were over 60 yr of age. Thirty-
four (17%) recipients were either Black (28-14%), 
Asian (4-2%), or Hispanic (2-1%). The causes of 
end stage renal disease are listed in Table 2; dia-
betes mellitus was the most common indication for 
transplantation. Eight (4%) patients had previously 
undergone orthotopic liver transplantation. 
Donor characteristics 
The mean donor age was 34.3 ± 20.1 yr. with a 
range of 0.3-75 yr (Table 3). There were 178 (87'1.,) 
cadaveric, and 26 (13%) living donors. Twenty-four 
(I3'Yo) of the cadaveric kidneys were from pediatric 
donors under the age of 3 yr and w~re t~nsplanted 
en bloc. 
The mean cold ischemia time was 31.4 ± 8.4 h. 
A breakdown of the HLA matches and mismatches 
is shown in Table 4. There were 7 (3%) six-antigen 
matches and 13 (6%) zero-antigen mismatches. 
The overall distribution of the patients in the 
Table 2. causes of end-stage renal disease 
FK506/pred FK506/azaipred Overall 
Diabetes melitus 29 (28%) 21 (21%) 50 (25%) 
Glomerulonephritis 18 (18%) 13 (13%) 31 (15%) 
Hypertension 11 (11%) 16 (16%) 27 (13%) 
Polycystic kidney disease 7 (7%) 10 (10'lr.) 17 (8%) 
Focal segmental glomerulo-
sclerosis 8 (8%l 5 (5%) 13 (6%) 
Pyeklnephritis 5 ER%F~ 3 (3%) 8 (4%) 
Systemic lupus erythemato-
sis 3 (3%) 6 (6%) 9 (4%) 
IgA nephropathy 0(0%) 5 (5%) 5 (2%) 
Hemolytic-uremic syndrome 2 (2%) 1 (1%) 3 (2%) 
Alport's 2 (2%) 1 (1%) 3 (2%) 
Unknown 8 (8%) 6 (6%) 14 (7%) 
Other 9 (9%) 15 (14%) 24 (12%) 
Table 3. Donor characteristics 
FK506Ipred FK506Iazalpred Overall 
Mean donor age (yrs) 34.2:1:19.4 34.3:1:20.8 34.3:1:20.1 
Range lK~9 0.3-75 0.3-75 
Mean cold Isc:hemia time 
(HRS) 31.6:1:8.3 31.3:1:8.7 31.4:1:8.4 
cadaver 84 (82\) 94(92%) 178 (8n.) 
'L.lving donor 18 (18%) 8 (8') 26 (132) 
En bloc 10 (12\) 14 (15'4) 24 E1~F 
• p<0.021. 
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Table 4. 
Ag 
o 
1 
2 
3 
4 
5 
6 
Ag 
6 
5 
4 
3 
2 
1 
o 
FK506Jpred 
8 (8') 
8 (8') 
24 (24') 
31 (301) 
18 (181) 
10 (10%) 
3 (3%) 
102 
FK506/pred 
5 (5%) 
7 (7%) 
15 (15%) 
32 (31%) 
26 (25%) 
14 (14\) 
3 (31) 
102 
Antigen mismatching 
FK506Jaza/pred 0vefaI1 
:i (5") 13 (6%) 
5 (5') 13 (6%) 
24 (24%) 48 (24%) 
31 (301) 62 (30\) 
22 (221.) 40 (20%) 
12 (121) 22 (11%) 
3 (3%) 6 (3%) 
102 204 
Antigen matching 
FK506/azalpred Overall 
2 (25%) 7 (3%) 
1 ('%) 8 (4%) 
13 (13%) 28 (14%) 
35 (34%) 67 (33%) 
26 (25%) 52 (25%) 
20 (20%) 34 (17%) 
5 (5') 8 (4") 
102 204 
two limbs of the trial was not statistically different 
with regard to the above parameters. with two 
exceptions; there were more elderly patients (i.e. 
over 60 yr of age) in the three-drug group (22% 
vs. II 'Yu - P < 0.04), and more living donor cases 
in the two-drug group (18% vs. 8% - P < 0.04). 
Immunosuppression - (Table 5) 
FK-506 - FK-506. O. t 5 mg/kg was given by mouth 
to all patients preoperatively. Intravenous FK-506, 
0.1 mg/kg/d as a continuous infusion, was started 
in the recovery room and was continued until the 
patients had return of gastrointestinal function and 
,were able to tolerate a diet. Oral FK-506 was then 
given at a dose of 0.15 mg/kg twice a day and then 
adjusted according to FK-506 levels. An attempt 
was made to achieve plasma levels of approximate-
Table 5. Immunosuppressive protocol 
FK-S06 Steroid 
Iy 1.5-2.0 ng/ml during the first few weeks after 
transplantation, although modification was often 
necessary because of toxicity or rejection. Target 
levels were gradually decreased to around 0.5-1 
ng/ml or less after the first few months. 
Steroids - All patients were given a bolus of 
1000 mg of intravenous methylprednisolone in the 
operating room after induction of anesthesia. Post-
operatively. patients received a short steroid recycle 
of 200-20 mg/ d of intravenous methylprednis-
olone over 6 d. Patients were then maintained on 
oral prednisone 20 mg/ d. Further tapering was 
individualized. 
Azathioprine - Patients randomized to receive 
azathioprine received 3 mg/kg as an oral dose 
preoperatively. The initial postoperative dose was 
3 mg/kg/d. and further adjustments were made 
based on the white blood cell count; the usual 
maintenance dose was 0.5-1.5 mg/kg/d. 
Randomization 
Random assignment of patients to either FK506/ 
prednisone or FK5061 azathioprine/ prednisone 
was done using 1 to 1 allocation via a variAble 
block randomization procedure. The blocks sizes 
were varied (block sizes = 4 and 8) and were ran-
domly selected with equal probability. The order 
of assignment within each block was determined 
by generating a random number between 0 and I 
using a random-number generator and then re-
arranging the random numbers in ascending order 
(13). The above procedure was repeated until all 
patients were randomized. 
Statistical analysis 
"-
The standard two-sample t-test was used to test 
differences in means while differences in pro-
portions were tested using Pearson's chi-square test 
of association. 
Patient survival was calculated from the date 
of kidney transplantation until death and graft 
Azathiopnne 
Preop 0.15 rng/kg/po Methylprednisolone IV 
1000 mg 
3 mglkg 
Postop 
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0.1 mg/kg IV 
Continuous i1TIusion 
0.15 mg/kg/po bid 
when takilg po . 
Methylprednisolone IV 
50 mg IV q 6 hx4 doses 
40 mg IV q 6 hx4 doses 
30 mg IV q 6 hx4 doses 
20 mg IV q 6 hx4 doses 
20 mg IV q 12 hx2 doses 
Prednisone 20 mg po qd 
3 mglkg/d 
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survival from the date of kidney transplantation _TabIe_6_, _______________ _ 
~ntil graft failure, retransplantation, or patient 
death. Survival curves were generated using the 
Kaplan-Meier (product-limit) method and were 
compared using the generalized Wilcoxon (Bres-
low) test. A multivariate Cox's regression analysis 
was perfonned to adjust the relative risk of graft 
failure between the two groups based on age of 
recipient (over 60 yr) and living donor cases. A 
stepwise procedure was perfonned to identify high-
risk patients for graft failure using all available 
infonnation collected. A p-value less than 0.05 was 
Infection 
Cancer 
Hepatitis 
Criac 
Disseminated intravascular 
coagulation 
Post surgical 
On dialysis 
considered statistically significant. 
Resllts ReJection 
The mean follow-up is 9 ±4 months, Infection Technical 
Death 
o;sease recurrence 
Patient survival 
Graft survival 
FK-506/pred 
0 
0 
1 
1 
0 
1 
FK-506/pred 
5 
a 
3 
1 
0 
Causes 01 death 
FK-506Iazalpred 
3 
2 
0 
0 
0 
1 
0 
Causes 01 graft loss 
FK-506/azalpred 
4 
5 
2 
4 
2 
Overall 
3 
2 
Overall 
9 
5 
5 
5 
2 
Overall I-yr actuarial survival was 93%; in the two-
drug group it was 95%, and in the three-drug group 
it was 91 % (Fig. I; P = 0.35). There were II deaths, 
4 in the two-drug and 7 in the three-drug group. 
The causes of death are listed in Table 6, 
One-year actuarial graft survival was 86%; in the 
two-drug group it was 90010, and in the three-drug 
University of Pittsburgh - Kidney Transplantation 811/91 - 10/11/92 
FK506/Prednisone vs FK506/Azathioprine/Prednisone 
Patient and Graft Survival 
100 
80 
-';te. 60 
-
«J 
> 
t 0 ,I ~ ~--:-:-:-:-~-:-:-:-:::::o=:o----------------------- " o ~- _, ___________ .. ... 
-~---~ ------------\..,r'""-----------6-----------
--Patient Survival 
-0- FKS06+Prednisone (n=102) 
K~ 40 
-0-FKS06+Azathioprine+Prednisone (n=102) 
::J 
en 
- - - - Graft Survival 
20 
- 0- FKS06+Prednisone (n=102) 
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Days After Transplantation 
rig. I. Patient and graft survival. 
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group it was 82% (Table 7; Fig. I; p=O.lO). The 
causes of graft loss are listed in Table 6. Cadaveric 
recipients had a I-yr graft survival of 85%, 89% in 
the two-drug and 82% in the three-drug group 
(p = 0.19). Living donor recipients had a I-yr graft 
survival of 92%, 94% in the two- and three-drug. 
groups. respectively (Fig. I; p=0.57). Results in 
patients undergoing primary of retransplantation; 
patients with PRA's below and above 40%; and 
patients under or over 60 years of age are shown 
in Table 7. There were no differences either between 
subgroups or immunosuppressive regimens. Non-
blacks had a I-yr graft survival of 85%, 91 % in the 
two-drug and 79% in the three-drug group (p = 
0.034): black recipients had a I-yr graft survival of 
96'1. •. 92% in the two-drug and 100% in the three-
drug groups (p = 0.28) (Table 7). 
Recipients of pediatric en bloc kidneys had a 1-
yr graft survival of 76%, with 79% and 71% (p= 
0.87) in the two- and three-drug groups; the out-
come in the remainder of cadaveric kidneys was 
87%, with 91% and 84% l-yr graft survival in the 
two- and three-drug groups (p=0.45 between en 
bloc and other cadaver kidneys). 
Acute tubular necrosis (ATN) was seen in 77 
(38%) patients; in the two-drug group, there were 
Table 7. Graft survival (one year - actuarial) 
FK ·506/pred FK·506/azalpred Overall 
M patients 901 82% 86\ 
Cadaveric 891 82% 85\ 
LMno donor 94\ 86\ 92% 
Am transplant 891 84\ an. 
Retransplant 93..- 7n. 85\ 
PRA <40\ 90% 84% 87\ 
PRA >40% 93% 75% 82% 
Age <60 91% 82% 87% 
Age ~SM 81% 83% 82% 
Black 92% 100% 96% 
+Non-black 91% 79% 85% 
En bloc 791 71% 76\ 
Other cadaver 91% 84% 87\ 
ATN 75\ 73\ 74\' 
-No ATN 100\ 87\ 93\ 
,. p-O.OO9. ' P < 0.00001. + p-0.034. 
Table 8. Renal function 
FK-506Ipred FK-506Iazalpred Overall 
Mean sen.rn creatinine 
mg/dl 1.88,*,0.70 1.82.0.85 1.85.0.76 
Median (mgJdI) 1.70 1.60 1.7Q 
Mean BUN (mgJdI) 31.15 3O:l:14 3O:l:14 
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42 (41.2%), and in the three-drug group, there were 
35 (34.3%) (p=0.312) patients with ATN. ATN 
was defined either by the absence of function in 
the first 48 h or by the requirement for dialysis in 
the 1 st wk after transplantation. Overall I-yr pa-
tient survival in the patients with and without ATN 
was 89010 and 95%; overall graft survival was 74% 
and 93% (p < 0.0000 I for differences in graft sur-
vival). There was no difference in l-yr graft sur-
vival between the two- and three-drug groups in 
the ATN group (75% and 73%), but graft survival 
in the non-ATN group was better in the two-drug 
group (100% vs. 87%, p=0.009). 
In a multivariate analysis performed on the pa-
tient and graft survival data, the only significant 
variable was the presence of ATN as a risk factor 
for graft survival. 
Renal function 
The mean serum creatinine was 1.85 ± O. 76 mgl dl. 
In the two- and three-drug groups it was 1.88 ± 0.70 
mg/dl and 1.82±0.85 mg/dl (p=0.299). The me-
dian creatinine was 1.7 mg/dl. The mean BUN 
was 30.3 ± 14.4 mgt dl; in the two- and three-drug 
groups, it was 30.8± 14.7 mg/dl and 29.7 ± 14.0 
mg/dl (p=0.621) (Table 8). There was no signifi-
cant difference between the two- and three-drug 
groups in these parameters. The plot of the serum 
creatinine and BUN over time is shown in Table 9 
and 10. 
Rejection (Table 9) 
Over 90% of rejection episodes were diagnosed 
by percutaneous renal biopsy. The incidence of 
rejection was 45%; in the two-drug group it was 
51 %, and in the three-drug group it was 39% (p = 
0.091). The rejection incidence in cadaveric recipi-
ents was 49%; it was 58% (49/84), and 39% (38/ 
94) in the two- and three-drug group (p=0.017). 
In living donor cases, the rejection incidence was 
19% (p=0.05, compared to cadaveric transplants); 
it was 16.7% (3118), and 25.0% (2/8) in the two-
and three-drug groups. The incidence in low and 
high PRA patients, younger and older recipients, 
and non-blak and black recipients is shown in 
Table 8: Rejection was seen more in high PRA 
patients and blacks, but there were no differences 
between the two- and three-drug groups in these 
parameters. 
Over 70% of the rejection episodes were steroid-
responsive. OKT3® or ATGAM® was used for ster-
oid-resistant rejection, except for 1 patient 
undergoing retransplantation who received induc-
tion OKT3®. Twenty-four (11.8%) patients re-
quired OKT3® or ATGAM®; in the two- and three-
• 
.. ~-K-..... ···-·~-----------.... a.a •• l!lllellJ!3"::IIII ..IKc;r~ 
I 
Table 9. 
Rejection 
FK-506/pred FK-506Iazalpred 0veraI 
AI patients 51% 39% 45' 
"cadaveR: 58%. 39% 49%+ 
Living donor 17% 25' 191 
PRA <401 46% 33' 401+ 
PRA ~4M1 80% 64% 701 
Age <60 53% 43% 48' 
Age ~SM 36% 27% 30% 
Black 85% 6O'lIo 71t,+ 
Non-bIack 46% 361. 41\ 
• p-0.017. + P < 005. 
Other complications 
FK·506/pred FK·506/azalpred Overall 
Cytomegalovirus 12% 12% 12% 
PTLO 1% 1% 1% 
'New onset diabetes 20% 8% 14\ 
• p-0.027. 
drug groups, the incidence ofOKT3® or ATGAM® 
requirement was 14.7% and 8.8% (p=0.192). 
Complications - (Table 9) 
Cytomegalovirus (CMV): CMV was seen in 24 
(12%) patients; the incidence was identical in the 
two- and three-drug groups. In general, the presence 
of either CMV infection or disease was enough to 
initiate treatment with intravenous gancyclovir. All 
patients received high-dose acyclovir prophylaxis; 
seronegative recipients of seropositive kidneys re-
ceived CMV hyperimmune globulin as well. 
Post-transplant lymphoprolijeratil'e disorder 
(PTLD): PTLD was seen in 2 patients, I each in 
the two- and three-drug groups. The patient in the 
two-drug group had not been treated for rejection 
prior to the diagnosis of PTLD; she developed G I 
lesions, as well as a focus in the renal allograft. 
The patient in the three-drug group had received 
steroids for rejection. His PTLD was limited to 
a few skin lesions. In the I st patient, the PTLD 
disappeared with cessation of the immunosuppres-
sion; she later experienced rejection, which was 
reversed with resumption of FK-506 and a short, 
low-dose steroid recycle. The 2nd patient had a 
significant decrease in immunosuppression, with 
prompt disappearance of the skin lesions. Both 
patients have stable functioning kidneys. 
There was 1 case of Kaposi's sarcoma diagnosed 
in a skin lesion in the three-drug group. She had 
"-K-I-"D~------ ... -........... . 
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returned home overseas and had temporarily been 
lost to follow-up. This lesion regressed with cess-
ation of FK-506 and a decrease in the prednisone 
dose. 
Diabetes Mellitus: Nev.·-onset insulin-dependent 
diabetes was seen in 20 (13.6%) patients, 14/69 
(20.2%) in the two-drug and 6178 (7.7%) in the 
three-drug group (p = 0.027). It was able to be dis-
continued in half of these patients after a reduction 
in the FK-506 and prednisone dosage. 
Immunosuppression 
FK-506: The FK-506 dosage and levels decreased 
over time in a similar manner in the two- and 
three-drug groups (Table I 0). The gradual decrease 
over time was an individualized clinical decision, 
and took into account the plasma level, as well as 
the presence of nephrotoxicity (either clinical or 
biopsy-proven), neurotoxicity (principally tr~p1or~ .. 
paresthesias of the extremities, and insomnia), in~ 
fectious complications, new onset diabetes an'd, oc-
casionally, hair loss. 
Steroids - (Table /0): Prednisone was tapered otT 
completely in 65/204 (32%) of patients, 32 (31.4%) 
in the two-drug and 33 (32.4%) in the three-drug 
groups. The overall prednisone dose was not differ-
ent between the two- and three-drug groups. 
Crossol'er: Azathioprine had to be discontinued in 
46 (45%) patients in the three-drug group at one 
time or another, because of a low white blood cell 
count or elevated liver function tests. Twenty-six 
Table 10 
FK·506 
FK·506/pred FK·506/azalpred Overall 
Dosage (mglkg/d) 0.1HO.10 0.18:1:0.10 0.17:1:0.10 
Level (ng/ml) 0.99:1:0.64 1.09:1:0.88 1.0:1:0.76 
Steroid withdrawal 
FK·506Ipred FK·506Iazalpred Overall 
31% 32% 32% 
Anti-hypertensi\/e medications 
Number FK-506Ipred FK-506Iazalpred Overall 
0 41% 45\ 43% 
1 O~ 35' 32% 
2 23\ 13\ 18% 
3 7\ 7\ 71 
4 1% 01 1\ 
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(25%) patients in the double-drug group at one 
time or another required the addition of azathio-
prine because of rejection. 
Cholesterol 
The mean serum cholesterol level was 193 ± 50 mg/ 
dl; it was nearly identical in the two- and three-
drug groups. 
Antihypertensive medications (Table 10) 
Eighty-eight (43%) patients are off antihyperten-
sive medications entirely; in the two- and three-
drug groups, there were 42 (41.2%,) and 46 (45°/.,) 
patients off antihypertension medications. 
Discussion 
New immunosuppressive agents are generally 
evaluated in carefully chosen patients and circum-
stances, i.e. first graft, low PRA, good early func-
tion. These ideal circumstances make it possible to 
assess the potential of the new agents unencum-
bered by the sort of complicated situations trans-
plant surgeons routinely face. From the outset of 
our experience with FK-506, a philosophic decision 
was made not to limit access to the drug to ideal 
patients and cases. While this made it possible for 
patients who had failed previous transplants to 
receive FK-506, it made analysis of the merits of 
the drug more complicated. In addition, learning 
to use FK-S06 in renal transplantation has been 
more difficult than in liver transplantation, primar-
ily because of its nephrotoxicity, but also because 
of the fact that the liver metabolizes FK-506 so 
quickly that the levels seen by the kidney are lower 
than those seen by the liver. Our impression has 
been that the nephrotoxicity of FK-506 has been 
comparable to that seen with cyclosporine (14). 
There has been an unquestionable learning curve 
with FK-S06 in renal transplantation. This is re-
flected in the I-yr actuarial graft survival statistics 
obtained between 1989 and 1991, 74% (8), and 
those obtained in the current series, 86%. Reason-
able results have been obtained with FK-S06 and, 
in our patient population, they are better than what 
we have seen under cyclosporine-based therapy 
(IS). The .ongoing ability to come off steroids in 
many patients is an additional advantage. Finally, 
the ability to achieve these results without induc-
tion antilymphocyte preparation may have econ-
omic consequences; a course of any of these agents 
can cost over $SOOO, and we are entering an era 
where a premium will be placed on trying to de-
crease costs. 
The utility of azathioprine as a third agent was 
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unclear in this study. There was a lower rejection 
rate in the triple-<irug group, in cadaveric recipi-
ents, and a lower incidence of new-onset diabetes; 
it was also necessary to add azathioprine in 2S% 
of the patients randomized to double therapy. 
However, there was no advantage in patient and 
graft survival overall, and in fact a worse outcome 
in graft survival in certain subgroups (non-black 
recipients and those with immediate allograft func-
tion). In addition, a substantial number could not 
tolerate azathioprine, with a crossover incidence 
(to the two-<irug group) of 4S%. Clearly, a subset 
of patients needs an additional agent, but azathio-
prine may not be the ideal third drug. It is possible 
that one of the new investigational agent, such as 
RS 61443 (16), Brequinar (17), Bredinin (18), or 
possibly Leflunomide (19), may be more useful. 
In this prospectively randomized group of pa-
tients, an extensive subgroup analysis was per-
formed to search for significant factors affecting 
both graft survival and the incidence t>f rejection. 
Although an argument could be made that such 
subgroup analysis is of questionable value, we 
found it helpful in understanding and interpreting 
our results. 
FK-S06 appears to be an efficacious drug for 
renal transplant patients. Reasonable patient and 
graft survival can be obtained, even in difficult 
cases. The agent requires some experience to be 
used optimally; it is our hope that other centers 
will learn from ours, so that they have a shorter 
learning curve when FK-506 is eventually released 
for general use. 
Acknowledgments 
We would like to thank Regioa Fenton, RN, BSN, CCTC. 
Loraine Kaminski, RN, Joan Murray R N, BSN, CCTC, Debor-
ah Good RN, BSN, CCTC, Holly Woods RN. CCTC, Marie 
Hawranko RN, CCTC, Jareen Flohr RN, BSN, Sue Bauder 
RN, Janice Zagari RN, BSN, and Jennifer Ovesney. RN. BSN, 
for their help with patient care; Janet Schmelzer for her help 
with data entry and organization; Dan Dziak for his help with 
data collection; David Krakosky for his help with graph and 
slide preparation; Kate Carr for her help with slide preparation; 
and Karen Blair for her help with typing the manuscript and 
table and slide preparation. 
Re.erences 
1. FUNG JJ, ABU-ELMAGO K, JAIN A, et al. A randomized trial 
of primary liver transplantation under immunosuppression 
with FK-506 vs. cyclosporine. Transplantation Proc 1991: 
23: 6: 2977-2983. 
2. STARZL TE, FuNG JJ, JORDAN M, et al. Kidney transplan-
tation under FK-506. JAMA 1990: 264: S~TK 
3. AIuarAGE JM, KollNOS RL, FUNG 11, STARZL TE. The 
clinical trial of FK-506 as a primary and rescue immuno-
suppression in adult cardiac transplantation. Transplan-
tation Proc 1991: 23: 6: 3054-3057. 
I 
4. GRlf}-ITIl BP, BANDO K, HARDESTY RL, et al. Prospective 
randomized trial of FK-S06 vs. cyciosporine. Presented at 
American Society of Transplant Surgeons Annual Meeting. 
1993. 
S. Tooo S, TZAKIS A, REYES J, et al. Clinical small bowel 
or smaIl bowel plus liver transplantation under FK-506. 
Transplantation Prole 1991: 23: 6: 3093-3098. 
6. RIcoRDI C, TZAKIS A, CARllOLL P, et a!. Human Islet Allo-
transplantation under FK-506. Transplantation Proc 1991: 
23: 6: 3207. 
7. SHAPIRO R, JORDAN M, FUNG 11, et al. Kidney transplan-
tation under FK-506 immunosuppression. Transplantation 
Proc 1991: 23: I: 920-923. 
8. SHAPIRO R, JORDAN M, SCANTLEBURY V, et aL FK-506 in 
clinical kidney transplantation. Transplantation Proc 1991: 
23: 6: 3065-3067. 
9. SHAPIRO R, JORDAN M, SCANTLEBURY VP. et al. Ran-
domized Trial of FK-506/Prednisone vs. FK-506! Azathio· 
prine! Prednisone after renal transplantation: Preliminary 
Report. Transplantation Proc 1993: 25: I: 669,,(,72. 
10. JAPANESE FK-506 STUDY GROUP. Japanese study of FK-
506 on kidney transplantation: Results of an early phase 
II study. Transplantation Proc 1991: 23: 6: 3071-3074. 
II. JAPANESE FK-506 STUDY GROUP. Japanese study of FK-
506 on kidnsy transplantation: Results of late phase II 
study. Transplantation Proc 1993: 25: I: 649..(,54. 
12. NEYLAN J, WHELCHEL J, LASKOW D, et al. Adverse events 
in the comparative dose finding trial of FK-S06 in primary 
renal transplantation. American Society of Transplant 
Physicians Annual Meeting, 1993. 
FK-506: double- vs. triple-drug therapy 
13. fRIEDMAN L, FURBERG CD, DEMEl'S DL. Fundamental of 
Clinical Trials, 2nd edn. Mosby Year Book, pages 54-56, 
1985. 
14. RANDHAWA PS, SHAPIRO R, JORDAN ML, STARZL TE, DE-
METRIS AJ. The histopathological changes associated with 
allograft rejection and drug toxicity in renal transplant 
recipients maintained on FK506: Clinical significance and 
comparison with cyclosporine. Am J Surg Pathol 1993: 17: 
I: 60-68. 
15. SHAPIRO R, TZ.o\KIS A. HAKALA T, et al. Cadaveric renal 
transplantation under the American Organ Allocation Sys· 
tem. In: Biotechnology in Renal Replacement Therapy 
(Eds. V. Bonomini, MP Scolari, Stefoni S, et al.) Contrib 
Nephrol Basel, Karger, 70: 30-40, 1989. 
16. SoLLINGER HW BEtERHOI MH. BELZER RO, DIETIlELM AG. 
KAUFFMAN RS. RS-61443 - A phase I clinical trial and 
pilot rescue study. Transplantation 1992: 53: 4OU~POK 
17. MAKOWKA L. CHAPMAN F. CRAMER DV. Historical develop-
ment of brequinar sodium as a new immunosuppressive 
drug for transplantation. Transplantation Proc 1993: 25: 3: 
2-7. 
18. TAJIMA A, HATA M. OHTA N, OHTAWARA Y. KAzuo S, 
Aso Y. Bredinin treatment in clinical kidney allografting. 
Transplantation 1984: 38: 2: 116-118. .• 
19. CHONG AS-F, GEBEL H, FINNEGAN A. et al. Lellunomide, 
a novel immunomodulatory agent: In vitro analyses of the 
mechanism of immunosuppression. Transplantation Proc 
1993: 25: I: 747-749. 
515 
